-
Product Insights
NewAlpha L-Iduronidase – Drugs In Development, 2024
The Alpha L-Iduronidase pipeline drugs market research report outlays comprehensive information on the Alpha L-Iduronidase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Metabolic Disorders, Central Nervous System, Musculoskeletal Disorders, and Oncology which include indications of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), Unspecified Central Nervous System Disorders, Unspecified Neurologic Disorders, Unspecified Musculoskeletal Disorders, and Unspecified Cancer....
-
Product Insights
NewIntegrin Alpha L – Drugs In Development, 2024
The Integrin Alpha L pipeline drugs market research report outlays comprehensive information on the Integrin Alpha L targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Ophthalmology, Immunology, Gastrointestinal, and Infectious Disease which include indications of Keratoconjunctivitis Sicca (Dry Eye), Psoriasis, Immunology, Inflammatory Bowel Disease, and Human Immunodeficiency Virus (HIV) Infections (AIDS). It also reviews key players involved...
-
Product Insights
NewAromatic L Amino Acid Decarboxylase – Drugs In Development, 2024
The Aromatic L Amino Acid Decarboxylase pipeline drugs market research report outlays comprehensive information on the Aromatic L Amino Acid Decarboxylase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Genetic Disorders, Ophthalmology, and Hematological Disorders which include indications of Parkinson's Disease, Psychiatric Disorders, Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency, Dry (Atrophic) Macular Degeneration, Wet...
-
Innovation Ranking
Innovation Ranking – L Brands Inc
Bath & Body Works Inc ((Bath & Body) formerly L Brands Inc, is a specialty retailer, operating both physical and online stores. The company’s product portfolio comprises women’s intimate and other apparel, body and bath products, personal care, and beauty products. It also offers lingerie, cosmetics, fragrances, lotions, shower gels, accessories, and soaps. Bath & Body markets products under the Bath and Body Works brand name. It merchandises products through company-operated retail stores, international franchises, licenses, websites, and wholesale partners....
-
Innovation Ranking
Innovation Ranking – L&T Technology Services Ltd
L&T Technology Services Ltd (L&T Technology), a subsidiary of Larsen & Toubro Ltd, is a provider of digital engineering, development and consultancy services. The company provides product, manufacturing and operating engineering services in the fields of mechanical, manufacturing automation, security, software development, smart factory, wearable IOT and embedded systems. Its service offerings include software and hardware product design and development, maintenance, testing and validations; agile supply chain; integrated content management; security monitoring; industrial AI and plant engineering; among others. L&T...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eladocagene Exuparvovec in Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eladocagene Exuparvovec in Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eladocagene Exuparvovec in Aromatic l-Amino Acid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Romyelocel-L in Chemotherapy Induced Neutropenia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Romyelocel-L in Chemotherapy Induced Neutropenia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Romyelocel-L in Chemotherapy Induced Neutropenia Drug Details: Romyelocel L (CLT-008) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – L And J-HZ in Herpes Zoster (Shingles)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - L And J-HZ in Herpes Zoster (Shingles) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. L And J-HZ in Herpes Zoster (Shingles) Drug Details:...
-
Product Insights
L&T – Malumichampatti IT Park – Tamil Nadu
The L&T – Malumichampatti IT Park – Tamil Nadu involves the construction of an IT park with a floor area of 171,870m2 in Coimbatore, Tamil Nadu, India. Equip yourself with the essential tools needed to make informed and profitable decisions with our L&T – Malumichampatti IT Park – Tamil Nadu report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and...
-
Product Insights
NewAromatic l-Amino Acid Decarboxylase (AADC) Deficiency – Drugs In Development, 2024
Empower your strategies with our Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency – Drugs In Development, 2024 report and make more profitable business decisions. Aromatic l-amino acid decarboxylase (AADC) deficiency is a disease that affects the production of signals that allow cells in the nervous system to communicate with each other. This is a rare neurotransmitter disorder. AADC is the last enzyme in the biosynthesis of dopamine and serotonin. The deficiency of AADC leads to metabolic disturbance of dopamine, norepinephrine, epinephrine, and...